Compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same

1. A compound of the following formula (1):

in the above formula (1)

A is selected from the following substituents A-i, A-ii, A-iii, A-iv, A-v, A-vi, A-vii and A-viii:

wherein

J represents hydrogen, halogen, or halogen-substituted or unsubstituted C 1 -C 6 -alkyl,

X represents O or S,

Z represents C or N,

E represents hydrogen, halogen, cyano, nitro, substituted or unsubstituted C 1 -C 6 -alkyl, or substituted or unsubstituted C 1 -C 6 -alkoxy,

D represents halogen, cyano, nitro, halogen-substituted or unsubstituted C 1 -C 6 -alkyl, —CHO, or —CH═N—OH,

Q is selected from the following substituents Q-i, Q-ii and Q-iii-1 to Q-iii-8:

(Q-i) hydrogen;

(Q-ii) C 1 -C 8 -alkyl which is unsubstituted or substituted by a group selected from halogen, hydroxyl, C 3 -C 7 -cycloalkyl and O—R 6 wherein R 6 represents C 1 -C 7 alkyl;

wherein W represents O or S, R7 represents hydrogen, or substituted or unsubstituted lower alkyl, and n denotes an integer of 0˜3;

wherein W represents O or S, R8 and R9 each represent hydrogen or lower alkyl, and m denotes an integer of 1˜3;

wherein R8 and R9 each represent hydrogen or lower alkyl, and m denotes an integer of 1˜3;

wherein R10 and R11 each represent hydrogen, halogen, lower alkoxy or lower alkyl, and m denotes an integer of 1˜3;

wherein R12 represents substituted or unsubstituted lower alkyl or aromatic group, and n denotes an integer of 0˜3;

wherein R13 and R14 each represent substituted or unsubstituted lower alkyl, or together with N to which they are attached may form a 3˜7 membered heterocycle, and n denotes an integer of 0˜3;

wherein R15 represents substituted or unsubstituted lower alkyl, and m denotes an integer of 1˜3;

wherein m denotes an integer of 1˜3;

Y represents hydrogen, halogen, substituted or unsubstituted, saturated or unsaturated, and straight-chain, branched or cyclic alkyl, substituted or unsubstituted C 1 -C 6 -alkoxy, or substituted or unsubstituted aromatic or heteroaromatic group, and

G represents hydrogen, or represents substituted or unsubstituted, saturated or unsaturated, and straight-chain, branched or cyclic alkyl,

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 wherein A is selected from the following substituents A-i, A-ii, A-iii, A-iv, A-v, A-vi, A-vii and A-viii:

wherein

J represents halogen-substituted or unsubstituted C 1 -C 4 -alkyl,

X represents O or S, and

Z represents C or N,

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 wherein E represents hydrogen, halogen, cyano or nitro,

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 wherein D represents halogen, cyano, nitro, or —CHO,

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 wherein Y represents hydrogen, C 1 -C 7 -alkyl, C 1 -C 7 -alkoxy-C 1 -C 7 -alkyl, or aromatic group,

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 wherein G represents hydrogen,

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 wherein

A is selected from the following substituents A-i, A-iv, A-v, A-vi and A-vii:

wherein

J represents halogen-substituted or unsubstituted C 1 -C 4 -alkyl,

X represents O or S, and

Z represents C or N,

E represents hydrogen or cyano,

D represents cyano or nitro,

Q is selected from the following substituents Q-i, Q-ii and Q-iii-1:

(Q-i) hydrogen;

(Q-ii) C 1 -C 8 -alkyl which is unsubstituted or substituted by a group selected from halogen, C 3 -C 7 -cycloalkyl and O—R 6 wherein R 6 represents C 1 -C 4 -alkyl;

wherein W represents O or S, R7 represents hydrogen or C 1 -C 4 -alkyl, and n denotes an integer of 0˜3;

Y represents hydrogen, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy-C 1 -C 4 -alkyl or phenyl, and

G represents hydrogen,

or a pharmaceutically acceptable salt thereof.

8. A compound which is selected from the following group:

1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid;

1-[3-cyano-1-(cyclopropylmethyl)indol-5-yl]pyrazole-4-carboxylic acid;

1-[3-cyano-1-cyclopropyl-indol-5-yl]pyrazole-4-carboxylic acid;

1-(3-cyano-1-isobutyl-indol-5-yl)pyrazole-4-carboxylic acid;

1-[3-cyano-1-(2,2-dimethylpropyl)indol-5-yl]pyrazole-4-carboxylic acid;

1-[3-cyano-1-(2-methoxyethyl)indol-5-yl]pyrazole-4-carboxylic acid;

1-(3-cyano-1-sec-butyl-indol-5-yl)-pyrazole-4-carboxylic acid;

1-[3-cyano-1-cyclobutyl-indol-5-yl]pyrazole-4-carboxylic acid;

1-(3-cyano-1-cyclopentyl-indol-5-yl)-pyrazole-4-carboxylic acid;

1-[3-cyano-1-(1-fluoropropan-2-yl)-indol-5-yl]-pyrazole-4-carboxylic acid;

1-[3-cyano-1-(tetrahydrofuran-3-yl)-indol-5-yl]-pyrazole-4-carboxylic acid;

1-[3-cyano-1-isopropyl-indol-5-yl]-3-methyl-pyrazole-4-carboxylic acid;

1-[3-cyano-1-(cyclopropylmethyl)indol-5-yl]-3-methyl-pyrazole-4-carboxylic acid;

1-[3-cyano-1-(2-methoxyethyl)indol-5-yl]-3-methyl-pyrazole-4-carboxylic acid;

1-[3-cyano-1-isopropyl-indol-5-yl]-3-(trifluoromethyl)pyrazole-4-carboxylic acid;

1-[3-cyano-1-(cyclopropylmethyl)indol-5-yl]-3-(trifluoromethyl)pyrazole-4-carboxylic acid;

1-(1-isopropyl-3-nitro-indol-5-yl)pyrazole-4-carboxylic acid;

1-(3-cyano-1-isopropyl-indol-5-yl)-1,2,4-triazole-3-carboxylic acid;

1-(3-cyano-1-isopropyl-indol-5-yl)imidazole-4-carboxylic acid;

5-(3-cyano-1-isopropyl-indol-5-yl)-thiophene-2-carboxylic acid;

2-(3-cyano-1-isopropyl-indol-5-yl)isonicotinic acid;

2-[3-cyano-1-(cyclopropylmethyl)-indol-5-yl]isonicotinic acid;

2-[3-cyano-1-(tetrahydrofuran-3-yl)-indol-5-yl]isonicotinic acid;

2-[3-cyano-1-(1-fluoropropan-2-yl)-indol-5-yl]isonicotinic acid;

2-[3-cyano-1-(2-methoxyethyl)-indol-5-yl]isonicotinic acid;

2-(3-cyano-1-isopropyl-indol-5-yl)-6-methylisonicotinic acid;

2-(1-isopropyl-3-nitro-indol-5-yl)isonicotinic acid;

1-(7-cyano-2-phenyl-1H-indol-5-yl)-pyrazole-4-carboxylic acid;

1-(7-cyano-2-isopropyl-1H-indol-5-yl)-pyrazole-4-carboxylic acid;

1-(7-cyano-2-methoxymethyl-1H-indol-5-yl)-pyrazole-4-carboxylic acid; and

1-(7-cyano-1H-indol-5-yl)-pyrazole-4-carboxylic acid,

or a pharmaceutically acceptable salt thereof.

9. A process for preparing the compound of formula (1), or a pharmaceutically acceptable salt thereof according to claim 1 characterized by the following Reaction Scheme (1):

in the above Reaction Scheme (1),

A, D, E, G, Y and Q are as defined in claim 1 , provided that Q is not hydrogen, and

L 1 represents a leaving group.

10. A process for preparing the compound of formula (1), or a pharmaceutically acceptable salt thereof according to claim 1 characterized by the following Reaction Scheme (2):

in the above Reaction Scheme (2),

A, D, E, G and Y are as defined in claim 1 .

11. The process of claim 10 , wherein the compound of formula (4) used as a starting material is prepared according to the following Reaction Scheme (3):

in the above Reaction Scheme (3), A, E, G and Y are as defined in claim 1 .

12. A pharmaceutical composition for the inhibition of xanthine oxidase, which comprises (a) a therapeutically effective amount of the compound of formula (1), or a pharmaceutically acceptable salt thereof according to claim 1 ; and (b) a pharmaceutically acceptable carrier, a diluent, an excipient or a combination thereof.

13. The composition of claim 12 , which is used for the treatment of diseases associated with human xanthine oxidase.

14. The composition of claim 13 wherein the diseases associated with human xanthine oxidase is selected from the group consisting of hyperuricemia, gout, heart failure, cardiovascular disease, hypertension, diabetes, complications of diabetes, kidney disease, inflammation, articular disease and inflammatory bowel disease.

15. The composition of claim 14 wherein the complications of diabetes is selected from the group consisting of hyperlipidemia, atherosclerosis, obesity, hypertension, retinosis and renal failure.